Search results

mogamulizumab (Poteligeo)

For the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.

cabozantinib (Cabometyx)

treatment of advanced renal cell carcinoma (RCC) in treatment-naïve adults with intermediate or poor risk per IMDC criteria

eculizumab (Soliris)

Treatment of adults with refractory generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive. 

melatonin (Slenyto)

For the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.

ravulizumab (Ultomiris)

For the treatment of patients with a body weight of 10kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

nintedanib (Ofev)

Treatment in adults of other chronic fibrosing interstitial lung diseases with a progressive phenotype.

niraparib (Zejula)

As monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

baricitinib (Olumiant)

Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.

acalabrutinib (Calquence)

As monotherapy or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL)

buprenorphine/naloxone (Suboxone)

Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Suboxone is indicated in adults and adolescents over 15 years of age who have agreed to be treated for addiction.

doravirine (Pifeltro)

In combination with other antiretroviral medicinal products, for the treatment of adults infected with human immunodeficiency virus 1 (HIV-1) without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class.

olaparib (Lynparza)

As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.

cabotegravir (Vocabria)

Cabotegravir long acting (CAB LA) injection is indicated, in combination with rilpivirine long acting (RPV LA) injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.

cabozantinib (Cabometyx)

in combination with nivolumab for the first-line treatment of advanced renal cell carcinoma in adults

empagliflozin (Jardiance)

In adults for treatment of symptomatic chronic heart failure with reduced ejection fraction.